Potent and Broad Inhibition of HIV-1 by a Peptide from the gp41 Heptad Repeat-2 Domain Conjugated to the CXCR4 Amino Terminus

PLoS Pathogens

Volumn 12, Issue 11, 2016, Pages

  Leslie, George J ^a   Wang, Jianbin ^b   Richardson, Max W ^c   Haggarty, Beth S ^a   Hua, Kevin L ^b   Duong, Jennifer ^b   Secreto, Anthony J ^c   Jordon, Andrea P O ^a   Romano, Josephine ^a   Kumar, Kritika E ^a   DeClercq, Joshua J ^b   Gregory, Philip D ^b   June, Carl H ^c   Root, Michael J ^d   Riley, James L ^c   Holmes, Michael C ^b   Hoxie, James A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b SANGAMO BIOSCIENCES INC   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; ENFUVIRTIDE; GLYCOPROTEIN GP 41; HR2 PEPTIDE; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; PEPTIDES AND PROTEINS; RNA DIRECTED DNA POLYMERASE; UNCLASSIFIED DRUG; PEPTIDE C34; PEPTIDE FRAGMENT;

AMINO ACID SEQUENCE; ANIMAL CELL; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MOUSE; NONHUMAN; VIRUS CELL INTERACTION; VIRUS ENTRY; VIRUS INHIBITION; VIRUS MUTATION; VIRUS REPLICATION; VIRUS RESISTANCE; ANIMAL; HEK293 CELL LINE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METABOLISM; NONOBESE DIABETIC MOUSE; VIROLOGY;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; FLOW CYTOMETRY; HEK293 CELLS; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HIV-1; HUMANS; MICE; MICE, INBRED NOD; PEPTIDE FRAGMENTS; RECEPTORS, CXCR4; VIRUS INTERNALIZATION;

EID: 85002157847     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1005983     Document Type: Article

References (89)

1. Chun TW, Davey RT, Engel D, Lane HC, Fauci AS, AIDS: Re-emergence of HIV after stopping therapy. Nature. 1999;401(6756):874–5. doi: 10.1038/4475510553903
2. Davey RT, Bhat N, Yoder C, Chun T-W, Metcalf JA, Dewar R, et al. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc Natl Acad Sci. 1999;96(26):15109–14. 10611346
3. Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, Pierson T, et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med. 1999;5(5):512–7. doi: 10.1038/839410229227
4. Barouch DH, Deeks SG, Immunologic strategies for HIV-1 remission and eradication. Science. 2014;345(6193):169–74. Epub 2014/07/12. PubMed Central PMCID: PMC4096716. doi: 10.1126/science.125551225013067
5. Schnittman S, Psallidopoulos M, Lane H, Thompson L, Baseler M, Massari F, et al. The reservoir for HIV-1 in human peripheral blood is a T cell that maintains expression of CD4. Science. 1989;245(4915):305–8. 2665081
6. Chomont N, El-Far M, Ancuta P, Trautmann L, Procopio FA, Yassine-Diab B, et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med. 2009;15(8):893–900. doi: 10.1038/nm.197219543283
7. Siliciano JD, Kajdas J, Finzi D, Quinn TC, Chadwick K, Margolick JB, et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med. 2003;9(6):727–8. doi: 10.1038/nm88012754504
8. Chun TW, Carruth L, Finzi D, Shen X, DiGiuseppe JA, Taylor H, et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature. 1997;387(6629):183–8. doi: 10.1038/387183a09144289
9. Kahn JO, Walker BD, Acute human immunodeficiency virus type 1 infection. N Engl J Med. 1998;339(1):33–9. doi: 10.1056/NEJM1998070233901079647878
10. Whitney JB, Hill AL, Sanisetty S, Penaloza-MacMaster P, Liu J, Shetty M, et al. Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys. Nature. 2014;512(7513):74–7.
11. Hütter G, Nowak D, Mossner M, Ganepola S, Müßig A, Allers K, et al. Long-term control of HIV by CCR5 delta32/delta32 stem-cell transplantation. N Engl J Med. 2009;360(7):692–8. doi: 10.1056/NEJMoa080290519213682
12. Shan L, Deng K, Shroff Neeta S, Durand Christine M, Rabi SA, Yang H-C, et al. Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immun. 2012;36(3):491–501.
13. Deng K, Pertea M, Rongvaux A, Wang L, Durand CM, Ghiaur G, et al. Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations. Nature. 2015;517(7534):381–5. doi: 10.1038/nature1405325561180
14. Hansen SG, Ford JC, Lewis MS, Ventura AB, Hughes CM, Coyne-Johnson L, et al. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature. 2011;473(7348):523–7. doi: 10.1038/nature1000321562493
15. Roos MT, Lange JM, de Goede RE, Coutinho RA, Schellekens PT, Miedema F, et al. Viral phenotype and immune response in primary human immunodeficiency virus type 1 infection. J Infect Dis. 1992;165(3):427–32. 1347054
16. Migueles SA, Connors M, Success and failure of the cellular immune response against HIV-1. Nature immunology. 2015;16(6):563–70. Epub May 19. doi: 10.1038/ni.316125988888
17. Mitsuyasu RT, Anton PA, Deeks SG, Scadden DT, Connick E, Downs MT, et al. Prolonged survival and tissue trafficking following adoptive transfer of CD4ζ gene-modified autologous CD4+ and CD8+ T cells in human immunodeficiency virus–infected subjects. Blood. 2000;96(3):785–93. 10910888
18. Walker RE, Bechtel CM, Natarajan V, Baseler M, Hege KM, Metcalf JA, et al. Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection. Blood. 2000;96(2):467–74. 10887107
19. Levine BL, Humeau LM, Boyer J, MacGregor R-R, Rebello T, Lu X, et al. Gene transfer in humans using a conditionally replicating lentiviral vector. Proc Natl Acad Sci. 2006;103(46):17372–7. doi: 10.1073/pnas.060813810317090675
20. Leibman RS, Riley JL, Engineering T Cells to Functionally Cure HIV-1Infection. Mol Ther. 2015;23(7):1149–59. Epub 2015/04/22. PubMed Central PMCID: PMCPmc4817793. doi: 10.1038/mt.2015.7025896251
21. Tebas P, Stein D, Tang WW, Frank I, Wang SQ, Lee G, et al. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med. 2014;370(10):901–10. doi: 10.1056/NEJMoa130066224597865
22. Tebas P, Stein D, Binder-Scholl G, Mukherjee R, Brady T, Rebello T, et al. Antiviral effects of autologous CD4 T cells genetically modified with a conditionally replicating lentiviral vector expressing long antisense to HIV. Blood. 2013;121(9):1524–33. doi: 10.1182/blood-2012-07-44725023264589
23. Wilen CB, Wang J, Tilton JC, Miller JC, Kim KA, Rebar EJ, et al. Engineering HIV-resistant human CD4+ T cells with CXCR4-specific zinc-finger nucleases. PLoS Pathog. 2011;7(4):e1002020. Epub 2011/05/03. PubMed Central PMCID: PMC3077364. doi: 10.1371/journal.ppat.100202021533216
24. Didigu CA, Wilen CB, Wang J, Duong J, Secreto AJ, Danet-Desnoyers GA, et al. Simultaneous zinc-finger nuclease editing of the HIV coreceptors CCR5 and CXCR4 protects CD4+ T cells from HIV-1 infection. Blood. 2014;123(1):61–9. doi: 10.1182/blood-2013-08-52122924162716
25. Hoxie JA, June CH, Novel cell and gene therapies for HIV. Cold Spr Harb Per Med. 2012;2(10):1–21. Epub 2012/10/03.
26. Egelhofer M, Brandenburg G, Martinius H, Schult-Dietrich P, Melikyan GB, Kunert R, et al. Inhibition of human immunodeficiency virus type 1 entry in cells expressing gp41-derived peptides. J Virol. 2004;78(2):568–75. Epub 2003/12/25. PubMed Central PMCID: PMC368739. doi: 10.1128/JVI.78.2.568-575.200414694088
27. Hildinger M, Dittmar MT, Schult-Dietrich P, Fehse B, Schnierle BS, Thaler S, et al. Membrane-anchored peptide inhibits human immunodeficiency virus entry. J Virol. 2001;75(6):3038–42. Epub 2001/02/27. PubMed Central PMCID: PMC115933. doi: 10.1128/JVI.75.6.3038-3042.200111222732
28. Perez EE, Riley JL, Carroll RG, von Laer D, June CH, Suppression of HIV-1 infection in primary CD4 T cells transduced with a self-inactivating lentiviral vector encoding a membrane expressed gp41-derived fusion inhibitor. Clinical immunology (Orlando, Fla). 2005;115(1):26–32. Epub 2005/05/05.
29. Melikyan GB, Egelhofer M, von Laer D, Membrane-anchored inhibitory peptides capture human immunodeficiency virus type 1 gp41 conformations that engage the target membrane prior to fusion. J Virol. 2006;80(7):3249–58. PubMed Central PMCID: PMCPMC1440409. doi: 10.1128/JVI.80.7.3249-3258.200616537592
30. Peterson CW, Younan P, Jerome KR, Kiem H-P, Combinatorial anti-HIV gene therapy: using a multipronged approach to reach beyond HAART. Gen Ther. 2013;20(7):695–702. Epub 12 SEP 2013.
31. Zahn RC, Hermann FG, Kim EY, Rett MD, Wolinsky SM, Johnson RP, et al. Efficient entry inhibition of human and nonhuman primate immunodeficiency virus by cell surface-expressed gp41-derived peptides. Gene Ther. 2008;15(17):1210–22. Epub 2008/05/02. PubMed Central PMCID: PMC2862551. doi: 10.1038/gt.2008.7318449216
32. Jv Lunzen, Glaunsinger T, Stahmer I, Baehr Vv, Baum C, Schilz A, et al. Transfer of autologous gene-modified T cells in HIV-infected patients with advanced immunodeficiency and drug-resistant virus. Mol Ther. 2007;15(5):1024–33. doi: 10.1038/mt.sj.630012417356541
33. Zahn R, Hermann F, Kim E, Rett M, Wolinsky S, Johnson R, et al. Efficient entry inhibition of human and nonhuman primate immunodeficiency virus by cell surface-expressed gp41-derived peptides. Gen Ther. 2008;15(17):1210–22.
34. Hermann FG, Martinius H, Egelhofer M, Giroglou T, Tonn T, Roth SD, et al. Protein scaffold and expression level determine antiviral activity of membrane-anchored antiviral peptides. Hum Gene Ther. 2009;20(4):325–36. Epub 2009/03/10. doi: 10.1089/hum.2006.15819267665
35. Younan PM, Polacino P, Kowalski JP, Peterson CW, Maurice NJ, Williams NP, et al. Positive selection of mC46-expressing CD4+ T cells and maintenance of virus specific immunity in a primate AIDS model. Blood. 2013;122(2):179–87. doi: 10.1182/blood-2013-01-48222423719296
36. Del Prete GQ, Leslie GJ, Haggarty B, Jordan AP, Romano J, Hoxie JA, Distinct molecular pathways to X4 tropism for a V3-truncated human immunodeficiency virus type 1 lead to differential coreceptor interactions and sensitivity to a CXCR4 antagonist. J Virol. 2010;84(17):8777–89. Epub 2010/06/25. PubMed Central PMCID: PMC2919036. doi: 10.1128/JVI.00333-1020573813
37. Root MJ, Kay MS, Kim PS, Protein design of an HIV-1 entry inhibitor. Science. 2001;291(5505):884–8. 11229405
38. Champagne K, Shishido A, Root MJ, Interactions of HIV-1 inhibitory peptide T20 with the gp41 N-HR coiled coil. J Biol Chem. 2009;284(6):3619–27. doi: 10.1074/jbc.M80926920019073602
39. Kahle K, Steger H, Root M, Asymmetric deactivation of HIV-1 gp41 following fusion inhibitor binding. PLoS Pathog. 2009;5(11):e1000674doi: 10.1371/journal.ppat.100067419956769
40. Gallo SA, Sackett K, Rawat SS, Shai Y, Blumenthal R, The stability of the intact envelope glycoproteins is a major determinant of sensitivity of HIV/SIV to peptidic fusion inhibitors. J Mol Bio. 2004;340(1):9–14.
41. Gustchina E, Hummer G, Bewley CA, Clore GM, Differential inhibition of HIV-1 and SIV envelope-mediated cell fusion by C34 peptides derived from the C-terminal heptad repeat of gp41 from diverse strains of HIV-1, HIV-2, and SIV. J Med Chem. 2005;48(8):3036–44. doi: 10.1021/jm049026h15828842
42. Chan DC, Fass D, Berger JM, Kim PS, Core structure of gp41 from the HIV envelope glycoprotein. Cell. 1997;89(2):263–73. Epub 1997/04/18. 9108481
43. Liu S, Lu H, Niu J, Xu Y, Wu S, Jiang S, Different from the HIV fusion inhibitor C34, the anti-HIV drug fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120. J Bio Chem. 2005;280(12):11259–73.
44. Pérez-Alvarez L, Carmona R, Ocampo A, Asorey A, Miralles C, Pérez de Castro S, et al. Long-term monitoring of genotypic and phenotypic resistance to T20 in treated patients infected with HIV-1. J Med Virol. 2006;78(2):141–7. doi: 10.1002/jmv.2052016372284
45. Baldwin CE, Sanders RW, Deng Y, Jurriaans S, Lange JM, Lu M, et al. Emergence of a drug-dependent human immunodeficiency virus type 1 variant during therapy with the T20 fusion inhibitor. J Virol. 2004;78(22):12428–37. Epub 2004/10/28. PubMed Central PMCID: PMCPmc525057. doi: 10.1128/JVI.78.22.12428-12437.200415507629
46. Lohrengel S, Hermann F, Hagmann I, Oberwinkler H, Scrivano L, Hoffmann C, et al. Determinants of human immunodeficiency virus type 1 resistance to membrane-anchored gp41-derived peptides. J Virol. 2005;79(16):10237–46. doi: 10.1128/JVI.79.16.10237-10246.200516051817
47. Carmona R, Pérez-Alvarez L, Muñoz M, Casado G, Delgado E, Sierra M, et al. Natural resistance-associated mutations to Enfuvirtide (T20) and polymorphisms in the gp41 region of different HIV-1 genetic forms from T20 naive patients. J Clin Virol. 2005;32(3):248–53. doi: 10.1016/j.jcv.2004.11.00915722032
48. Richardson MW, Guo L, Xin F, Yang X, Riley JL, Stabilized human TRIM5alpha protects human T cells from HIV-1 infection. Molecular therapy: the journal of the American Society of Gene Therapy. 2014;22(6):1084–95. PubMed Central PMCID: PMCPMC4048901.
49. Mukherjee R, Plesa G, Sherrill-Mix S, Richardson MW, Riley JL, Bushman FD, HIV sequence variation associated with env antisense adoptive T-cell therapy in the hNSG mouse model. Mol Ther. 2010;18(4):803–11. Epub 2010/01/28. PubMed Central PMCID: PMC2862538. doi: 10.1038/mt.2009.31620104212
50. Richardson MW, Carroll RG, Stremlau M, Korokhov N, Humeau LM, Silvestri G, et al. Mode of transmission affects the sensitivity of human immunodeficiency virus type 1 to restriction by rhesus TRIM5alpha. J Virol. 2008;82(22):11117–28. Epub 2008/09/05. PubMed Central PMCID: PMCPmc2573261. doi: 10.1128/JVI.01046-0818768965
51. Perez EE, Wang J, Miller JC, Jouvenot Y, Kim KA, Liu O, et al. Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nat Biotechnol. 2008;26(7):808–16. PubMed Central PMCID: PMC3422503. doi: 10.1038/nbt141018587387
52. Chun T-W, Stuyver L, Mizell SB, Ehler LA, Mican JAM, Baseler M, et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci. 1997;94(24):13193–7. 9371822
53. Pierson T, McArthur J, Siliciano RF, Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy. Ann Rev Immunol. 2000;18(1):665–708.
54. Chun T-W, Nickle DC, Justement JS, Meyers JH, Roby G, Hallahan CW, et al. Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy. J Infect Dis. 2008;197(5):714–20. doi: 10.1086/52732418260759
55. Churchill MJ DS, Margolis DM, Siliciano RF, Swanstrom R, HIV reservoirs: what, where and how to target them. Nat Rev Microb. 2016;14(1):55–60.
56. Cohn Lillian B, Silva Israel T, Oliveira Thiago Y, Rosales Rafael A, Parrish Erica H, Learn Gerald H, et al. HIV-1 integration landscape during latent and active infection. Cell. 2015;160(3):420–32. doi: 10.1016/j.cell.2015.01.02025635456
57. Kearney MF, Wiegand A, Shao W, Coffin JM, Mellors JW, Lederman M, et al. Origin of rebound plasma HIV includes cells with identical proviruses that are transcriptionally active before stopping of antiretroviral therapy. J Virol. 2016;90(3):1369–76.
58. Lorenzo-Redondo R, Fryer HR, Bedford T, Kim E-Y, Archer J, Kosakovsky Pond SL, et al. Persistent HIV-1 replication maintains the tissue reservoir during therapy. Nature. 2016;530(7588):51–6. doi: 10.1038/nature1693326814962
59. Bullen CK LG, Durand CM, Siliciano JD, Siliciano RF, New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo. Nat Med. 2014;20(4):425–9. doi: 10.1038/nm.348924658076
60. Cummins NW, Sainski AM, Dai H, Natesampillai S, Pang Y-P, Bren GD, et al. Prime, shock, and kill: Priming CD4 T cells from HIV patients with a BCL-2 antagonist before HIV reactivation reduces HIV reservoir size. J Virol. 2016;Epub Feb 3.
61. Millán J, Cerny J, Horejsi V, Alonso M, CD4 segregates into specific detergent-resistant T-cell membrane microdomains. Tiss Antig. 1999;53(1):33–40.
62. Nguyen DH, Taub D, CXCR4 function requires membrane cholesterol: implications for HIV infection. J Immun. 2002;168(8):4121–6. 11937572
63. Liao Z, Cimakasky LM, Hampton R, Nguyen DH, Hildreth JE, Lipid rafts and HIV pathogenesis: host membrane cholesterol is required for infection by HIV type 1. AIDS Res Hum Retrovirus. 2001;17(11):1009–19.
64. Popik W, Alce TM, Au W-C, Human immunodeficiency virus type 1 uses lipid raft-colocalized CD4 and chemokine receptors for productive entry into CD4+ T cells. J Virol. 2002;76(10):4709–22. doi: 10.1128/JVI.76.10.4709-4722.200211967288
65. Kamiyama H, Yoshii H, Tanaka Y, Sato H, Yamamoto N, Kubo Y, Raft localization of CXCR4 is primarily required for X4-tropic human immunodeficiency virus type 1 infection. Virol. 2009;386(1):23–31.
66. Mañes S, del Real G, Lacalle RA, Lucas P, Gómez Moutón C, Sánchez Palomino S, et al. Membrane raft microdomains mediate lateral assemblies required for HIV‐1 infection. EMBO reports. 2000;1(2):190–6. doi: 10.1093/embo-reports/kvd02511265761
67. Doms RW, Beyond receptor expression: the influence of receptor conformation, density, and affinity in HIV-1 infection. Virol. 2000;276(2):229–37.
68. Kuhmann SE, Platt EJ, Kozak SL, Kabat D, Cooperation of multiple CCR5 coreceptors is required for infections by human immunodeficiency virus type 1. J Virol. 2000;74(15):7005–15. 10888639
69. Isik N, Hereld D, Jin T, Fluorescence Resonance Energy Transfer Imaging Reveals that Chemokine-Binding Modulates Heterodimers of CXCR4 and CCR5 Receptors. PLoS ONE. 2008;3(10):e3424. doi: 10.1371/journal.pone.000342418923649
70. Contento RL, Molon B, Boularan C, Pozzan T, Manes S, Marullo S, et al. CXCR4–CCR5: A couple modulating T cell functions. Proceedings of the National Academy of Sciences. 2008;105(29):10101–6.
71. Cohen FS, Melikyan GB, The energetics of membrane fusion from binding, through hemifusion, pore formation, and pore enlargement. J Memb Bio. 2004;199(1):1–4.
72. Miyauchi K, Kozlov MM, Melikyan GB, Early steps of HIV-1 fusion define the sensitivity to inhibitory peptides that block 6-helix bundle formation. PLoS Pathog. 2009;5(9):e1000585. doi: 10.1371/journal.ppat.100058519763181
73. Furuta RA, Wild CT, Weng Y, Weiss CD, Capture of an early fusion-active conformation of HIV-1 gp41. Nature structural biology. 1998;5(4):276–9. Epub 1998/04/18. 9546217
74. Weiss CD, HIV-1 gp41: mediator of fusion and target for inhibition. AIDS Rev. 2002;1(4):214–21.
75. Reeves JD, Gallo SA, Ahmad N, Miamidian JL, Harvey PE, Sharron M, et al. Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics. Proc Natl Acad Sci. 2002;99(25):16249–54. doi: 10.1073/pnas.25246939912444251
76. Qin L, Kufareva I, Holden LG, Wang C, Zheng Y, Zhao C, et al. Crystal structure of the chemokine receptor CXCR4 in complex with a viral chemokine. Science. 2015;347(6226):1117–22. doi: 10.1126/science.126106425612609
77. Wu B, Chien EY, Mol CD, Fenalti G, Liu W, Katritch V, et al. Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science. 2010;330(6007):1066–71. doi: 10.1126/science.119439620929726
78. Tan Q, Zhu Y, Li J, Chen Z, Han GW, Kufareva I, et al. Structure of the CCR5 chemokine receptor–HIV entry inhibitor maraviroc complex. Science. 2013;341(6152):1387–90. doi: 10.1126/science.124147524030490
79. Huang C-C, Lam SN, Acharya P, Tang M, Xiang S-H, Hussan SS-u, et al. Structures of the CCR5 N terminus and of a tyrosine-sulfated antibody with HIV-1 gp120 and CD4. Science. 2007;317(5846):1930–4. doi: 10.1126/science.114537317901336
80. Farzan M, Choe H, Vaca L, Martin K, Sun Y, Desjardins E, et al. A tyrosine-rich region in the N terminus of CCR5 is important for human immunodeficiency virus type 1 entry and mediates an association between gp120 and CCR5. Journal of Virology. 1998;72(2):1160–4. 9445013
81. Farzan M, Mirzabekov T, Kolchinsky P, Wyatt R, Cayabyab M, Gerard NP, et al. Tyrosine sulfation of the amino terminus of CCR5 facilitates HIV-1 entry. Cell. 1999;96(5):667–76. 10089882
82. Porter DL, Levine BL, Kalos M, Bagg A, June CH, Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365(8):725–33. doi: 10.1056/NEJMoa110384921830940
83. Porter DL, Hwang W-T, Frey NV, Lacey SF, Shaw PA, Loren AW, et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Trans Med. 2015;7(303):303ra139–303ra139.
84. Levine B, Mosca J, Riley J, Carroll R, Vahey M, Jagodzinski L, et al. Antiviral effect and ex vivo CD4+ T cell proliferation in HIV-positive patients as a result of CD28 costimulation. Science. 1996;272(5270):1939–43. 8658167
85. June CH, Levine BL, T cell engineering as therapy for cancer and HIV: our synthetic future. Philos Trans R Soc Lond B Biol Sci. 2015;370(1680).
86. Montini E, Cesana D, Schmidt M, Sanvito F, Ponzoni M, Bartholomae C, et al. Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotech. 2006;24(6):687–96.
87. Follenzi A, Ailles LE, Bakovic S, Geuna M, Naldini L, Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences. Nature genetics. 2000;25(2):217–22. doi: 10.1038/7609510835641
88. Endres MJ, Clapham PR, Marsh M, Ahuja M, Turner JD, McKnight A, et al. CD4-independent infection by HIV-2 is mediated by fusin/CXCR4. Cell. 87(4):745–56. 8929542
89. Wang J, Harada A, Matsushita S, Matsumi S, Zhang Y, Shioda T, et al. IL-4 and a glucocorticoid up-regulate CXCR4 expression on human CD4+ T lymphocytes and enhance HIV-1 replication. J Leukoc Biol. 1998;64(5):642–9. 9823770